ORMP - Oramed Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.9300
-0.1200 (-3.93%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.0500
Open3.0300
Bid2.8500 x 1800
Ask3.7800 x 1000
Day's Range2.8700 - 3.0500
52 Week Range2.3200 - 6.0500
Volume43,809
Avg. Volume136,214
Market Cap52.276M
Beta (5Y Monthly)1.88
PE Ratio (TTM)N/A
EPS (TTM)-0.7210
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
  • Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA
    PR Newswire

    Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive feedback from its initial End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss Chemistry Manufacturing and Control (CMC) of its lead oral insulin capsule ORMD-0801.

  • ORMP: Oramed announces positive results from cohort 2 of Phase 2 trial with ORMD-0801 in T2D patients
    Zacks Small Cap Research

    ORMP: Oramed announces positive results from cohort 2 of Phase 2 trial with ORMD-0801 in T2D patients

    By Anita Dushyanth, PhD NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Results of the Phase 2b Trial The primary objective of the Phase II study was to explore therapeutic efficacy in patients and more importantly, determine the dose(s) and regimen for Phase III trials. A double blind, randomized 90-day dosing trial (Phase 2b), which was funded by ORMD, was designed to evaluate the efficacy of

  • Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million
    PR Newswire

    Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or "Company"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $4.00 per share. All of the shares in the offering are to be sold by Oramed. Oramed has granted the underwriters a 45-day option to purchase up to 787,500 additional shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about March 2, 2020, subject to the satisfaction of customary closing conditions.

  • Benzinga

    The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate ...

  • Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock
    PR Newswire

    Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock

    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the underwritten public offering are to be sold by Oramed. Oramed intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less the underwriting discount.

  • Have Insiders Been Buying Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Oramed to Present at BIO CEO & Investor Conference
    PR Newswire

    Oramed to Present at BIO CEO & Investor Conference

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the BIO CEO & Investor Conference in New York City.

  • Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board
    PR Newswire

    Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board

    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Dr. Julio Rosenstock to its Scientific Advisory Board.

  • Oramed Patent in Europe to be Granted for Oral Delivery of Proteins
    PR Newswire

    Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has indicated its intent to grant the Company a patent for its invention titled "Methods and Compositions for Oral Administration of Proteins," addressing oral compositions comprising protease inhibitors, which are a key component of the platform technology that protects therapeutic proteins in the digestive system.

  • Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
    PR Newswire

    Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

    NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board.

  • Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board
    PR Newswire

    Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board

    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, MD to its Scientific Advisory Board.

  • Oramed Pharmaceuticals Issues Letter to Shareholders
    PR Newswire

    Oramed Pharmaceuticals Issues Letter to Shareholders

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief Executive Officer Nadav Kidron. For a video message from Mr. Kidron click here.

  • Does Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Pay Compare Well With Peers?
    Simply Wall St.

    Does Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Pay Compare Well With Peers?

    Nadav Kidron became the CEO of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in 2006. First, this article will compare CEO...

  • ORMP: Multiple Data Readouts on the Horizon…
    Zacks Small Cap Research

    ORMP: Multiple Data Readouts on the Horizon…

    By Anita Dushyanth, PhD NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Financial Update On November 27, 2019, Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) filed form 10-K with financial results for the fiscal year 2019 ending August 31, 2019. The company reported revenues of $2.7 million for the fiscal year 2019 compared to $2.4 million for 2018. The revenues are related to the license agreement

  • Hedge Funds Have Never Been This Bullish On Oramed Pharmaceuticals Inc. (ORMP)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Oramed Pharmaceuticals Inc. (ORMP)

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]

  • Oramed Appoints Dr. Arie Mayer to Board of Directors
    PR Newswire

    Oramed Appoints Dr. Arie Mayer to Board of Directors

    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Arie Mayer, Ph.D. to its Board of Directors.

  • Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Dropped 41% In The Last Three Years
    Simply Wall St.

    Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Dropped 41% In The Last Three Years

    Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shareholders will doubtless be very grateful to see the share price up 32...

  • Oramed to Present a Scientific Poster at International Diabetes Federation Congress
    PR Newswire

    Oramed to Present a Scientific Poster at International Diabetes Federation Congress

    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it will present a scientific poster at the 2019 International Diabetes Federation (IDF) Congress in Busan, South Korea to be held December 2-6. Oramed's Chief Scientific Officer, Dr. Miriam Kidron, will present the poster.

  • Oramed working on first insulin pill for diabetes
    Yahoo Finance Video

    Oramed working on first insulin pill for diabetes

    Oramed Pharmaceuticals is waiting on approval from the FDA after its new insulin pill to treat type two diabetes had successful results in its phase two trial. Oramed Pharmaceuticals CEO Nadav Kidron joins Yahoo Finance’s Brian Sozzi and Alexis Christoforous to discuss on The First Trade.

  • Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology
    PR Newswire

    Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology

    NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the technology "Protease Inhibitor – Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same" has been granted by the Japanese Patent Office. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
    PR Newswire

    Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event

    NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted an investor event and conference call yesterday, November 18, 2019, where a panel of investigators and Key Opinion Leaders presented detailed findings from the Company's successful Phase IIb study of ORMD-0801 in the treatment of type 2 diabetes. Panelists presenting the data included: Dr. Joel Neutel, Principal Investigator of the study and Director of Research at Orange County Research Center; Kenneth Homer, the trial's biostatistician; Dr. Ramachandra Naik, Professor of Medicine/Endocrinology at SUNY Upstate Medical University; and Dr. Alexander Fleming, CEO of Kinexum, and former Head of Clinical Review of Endocrine and Metabolic Drugs at the U.S. Food and Drug Administration (FDA).

  • Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
    PR Newswire

    Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

    NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • PR Newswire

    Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes

    NEW YORK, November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes.

  • How Does Investing In Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Impact The Volatility Of Your Portfolio?
    Simply Wall St.

    How Does Investing In Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Impact The Volatility Of Your Portfolio?

    Anyone researching Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) might want to consider the historical volatility of the...